1. | rudihorne | |
2. | flowcobra | |
3. | ResearcherOfStocks | |
4. | BuyHighSellLow | |
5. | vote4amazon |
1. | rudihorne | |
2. | flowcobra | |
3. | ResearcherOfStocks | |
4. | BuyHighSellLow | |
5. | vote4amazon |
1. | flowcobra 10/10/2017 CEO just bought 9k shares after market. |
2. | ResearcherOfStocks 10/05/2017 Outlook for FDA Approval of Zilretta |
3. | rudihorne 04/18/2018 Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery |
4. | blackopsstreet 04/25/2018 Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018 |
5. | vote4amazon 02/01/2018 Berenberg initiates as a buy |
6. | BuyHighSellLow 10/10/2017 I sold last week in 31's |
7. | flowcobra 10/05/2017 Hits mid 30's Friday or Monday. |
8. | flowcobra 10/08/2017 Should should be good |
9. | BuyHighSellLow 10/05/2017 CEO has also made it clear that most OA knee patients will eventually need knee replacement surgery. 2nd line treatments delay it. Read this is you have a chance: {Link} |